New Once-Daily Version of Tramadol Approved for Chronic Pain
The US Food and Drug Administration has approved Labopharms once-daily extended-release formulation of the analgesic tramadol (Ryzolt) for the management of moderate to moderately severe chronic pain in adults who require around-the-clock long-term treatment of pain.
The US Food and Drug Administration has approved Labopharms once-daily extended-release formulation of the analgesic tramadol (Ryzolt) for the management of moderate to moderately severe chronic pain in adults who require around-the-clock long-term treatment of pain.
Ryzolt is a centrally acting analgesic with both immediate-release and extended-release characteristics. Labopharms US marketing partner, Purdue Pharma, anticipates launching the drug in 100-mg, 200-mg, and 300-mg tablets in the second quarter of 2009.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
